Cellect Announces Positive Clinical Trial Results

ApoGraft TM, Cellect’s flagship technology, validated as safe, robust and reproducible process for clinical use after a 104 donor test base
Cellect CEO: “In plain words, these positive results bring us one step closer to making stem cell therapies safe, effective and available”
 
TEL AVIV, Israel, Feb. 21, 2017  -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cell selection technology, announced today positive final results from its clinical trial of ApoGraft™ in healthy donors. The study’s primary objective was to validate the Company's propriety method of stem cell selection by going through the process of production and characterization with ApoGraft™, and was conducted on samples obtained in collaboration with two leading medical centers in Israel, The Schneider Children's Medical Center and the Rambam Medical Center.
Read more: Cellect Biotechnology Ltd ( APOP )

Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients

Novel Approach Offers Eye Care Practitioners Delivery Alternative for Post-Operative Therapeutic Regimens 
 
LAVAL, Quebec and WALTHAM, Mass., Feb. 21, 2017 -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
Read more: EyeGate Pharmaceuticals Inc ( EYEG )

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene ® and low dose Proleukin ® in REmission MAINtenance in Acute Myeloid Leukemia

Ceplene Currently Approved in Europe and Israel
REMAIN™ to be a pivotal study for US approval
 
NEW YORK, Feb. 17, 2017  -- Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international Overall Survival clinical study with the combination of Ceplene®, the Company's flagship product for Acute Myeloid Leukemia (AML) remission maintenance and relapse prevention, and low dose Proleukin®. Patient recruitment is expected to start in later 2017.
Read more: Immune Pharmaceuticals( IMNP )

Cannabix Technologies Provides Update on Marijuana Breathalyzer Development

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety as Canada gets set to table marijuana legalization this spring
 
VANCOUVER, BRITISH COLUMBIA--( Feb. 16, 2017) - Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to provide a development update on its FAIMS Beta 2.0 (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of ∆9-tetrahydrocannabinol ("THC") in human breath. Development in Gainesville, Florida and Vancouver, BC is progressing well and the Company expects to begin pre-trial live subject testing during the month of March.
Read more: Cannabix Technologies ( BLO )

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

TORONTO, ONTARIO--(Feb. 16, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the Company is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.
 
"Through our dedicated bioinformatics platform specifically designed to identify repurposed and innovative drug and plant-based treatments, such as cannabinoids, and with consultation of our experts in cannabinoid research, we have identified potential cannabinoid-based lead opportunities in a number of liver diseases," said Craig Leon, Chief Executive Officer of Revive. "We expect these initiatives to progress in the near-term and we will update the medical and investment communities as they occur."
Read more: Revive Therapeutics ( RVV )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker